Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OVR034
MIFTS: 38

Ovarian Clear Cell Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Ovarian Clear Cell Adenocarcinoma

About this section

MalaCards integrated aliases for Ovarian Clear Cell Adenocarcinoma:

Name: Ovarian Clear Cell Adenocarcinoma 12 15 17 71

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:5304
NCIt 49 C40078
SNOMED-CT 67 763131005
UMLS 71 C1518693
Sources

Summaries for Ovarian Clear Cell Adenocarcinoma

About this section
Disease Ontology : 12 A ovarian adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Ovarian Clear Cell Adenocarcinoma is related to clear cell adenocarcinoma and adenofibroma. An important gene associated with Ovarian Clear Cell Adenocarcinoma is ARID1A (AT-Rich Interaction Domain 1A), and among its related pathways/superpathways are Pathways in cancer and Glioma. The drugs Sunitinib and Protein Kinase Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include ovary, colon and kidney, and related phenotypes are cardiovascular system and endocrine/exocrine gland

Sources

Related Diseases for Ovarian Clear Cell Adenocarcinoma

About this section

Diseases related to Ovarian Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 149)
# Related Disease Score Top Affiliating Genes
1 clear cell adenocarcinoma 31.0 TP53 PIK3CA NAPSA HOXA10 HNF1B ARID1A
2 adenofibroma 30.8 TP53 NAPSA ARID1A
3 mucinous adenocarcinoma 30.7 TP53 PGR ESR2
4 ovarian clear cell adenofibroma 30.6 PIK3CA NAPSA
5 endometriosis 30.5 TP53 PGR HOXA10 HNF1B ESR2
6 serous cystadenocarcinoma 30.5 TP53 PIK3CA PGR ESR2 ARID1A
7 clear cell adenofibroma 30.3 SMARCA4 PIK3CA NAPSA ARID1A
8 endometriosis of ovary 30.1 PGR HNF1B ESR2 ARID1A
9 cystadenocarcinoma 29.9 TP53 PIK3CA PGR ESR2
10 ovary adenocarcinoma 29.5 TP53 SMARCA4 PIK3CA PGR HNF1B ARID1A
11 clear cell renal cell carcinoma 29.3 TP53 MTOR MET HIF1A ARID1A
12 ovarian serous cystadenocarcinoma 29.0 TP53 PIK3CA PGR HIF1A ESR2 ARID1A
13 renal cell carcinoma, nonpapillary 28.9 TP53 PIK3CA NAPSA MTOR MET HNF1B
14 ovarian clear cell carcinoma 28.4 TP53 PIK3CA NAPSA MTOR MET HNF1B
15 lung cancer susceptibility 3 28.4 TP53 STMN1 PIK3CA NAPSA MTOR MET
16 endometrial cancer 28.2 TP53 PIK3CA PGR MTOR HOXA10 HIF1A
17 clear cell adenocarcinoma of the ovary 12.1
18 adenocarcinoma 10.9
19 ovarian cancer 10.5
20 rare head and neck tumor 10.5 TP53 PIK3CA
21 appendix adenocarcinoma 10.4
22 ovarian epithelial cancer 10.4
23 rare adenocarcinoma of the breast 10.4 TP53 PIK3CA
24 ovarian carcinosarcoma 10.3 TP53 PIK3CA ARID1A
25 uterine body mixed cancer 10.3 TP53 PIK3CA ARID1A
26 krukenberg carcinoma 10.3 NAPSA HNF1B
27 uterine corpus endometrial carcinoma 10.3 TP53 PIK3CA ARID1A
28 ovarian cystadenocarcinoma 10.3 TP53 PIK3CA ARID1A
29 dermatosis papulosa nigra 10.3 PIK3CA MTOR
30 ovarian serous carcinoma 10.3
31 ovarian mixed germ cell neoplasm 10.3 PIK3CA MTOR
32 bartholin's gland adenoma 10.2 TP53 PGR
33 bartholin's gland benign neoplasm 10.2 TP53 PGR
34 vestibular gland benign neoplasm 10.2 TP53 PGR
35 breast papillary carcinoma 10.2 PIK3CA PGR
36 neutropenia 10.2
37 endometrial squamous cell carcinoma 10.2 TP53 PGR
38 large cell acanthoma 10.2 TP53 MTOR
39 basaloid lung carcinoma 10.2 TP53 PGR
40 ovarian seromucinous carcinoma 10.2 TP53 PGR
41 acanthoma 10.2 TP53 PIK3CA MTOR
42 apocrine adenosis of breast 10.2 TP53 PGR
43 keratosis, seborrheic 10.2 TP53 PIK3CA MTOR
44 comedo carcinoma 10.2 TP53 PGR
45 cervical clear cell adenocarcinoma 10.1 PGR NAPSA
46 bizarre leiomyoma 10.1 TP53 PGR
47 breast adenoid cystic carcinoma 10.1 TP53 PGR
48 malignant epithelial tumor of ovary 10.1
49 parameningeal embryonal rhabdomyosarcoma 10.1 TP53 PIK3CA
50 carcinosarcoma 10.1 TP53 PIK3CA PGR

Graphical network of the top 20 diseases related to Ovarian Clear Cell Adenocarcinoma:



Diseases related to Ovarian Clear Cell Adenocarcinoma
Sources

Symptoms & Phenotypes for Ovarian Clear Cell Adenocarcinoma

About this section

MGI Mouse Phenotypes related to Ovarian Clear Cell Adenocarcinoma:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 ARID1A ESR2 GPX3 HIF1A HOXA10 MET
2 endocrine/exocrine gland MP:0005379 10.31 ARID1A CBX7 ESR2 HIF1A HNF1B HOXA10
3 growth/size/body region MP:0005378 10.29 ARID1A CBX7 ESR2 GPX3 HIF1A HNF1B
4 cellular MP:0005384 10.26 ARID1A CBX7 ESR2 HIF1A HNF1B MET
5 homeostasis/metabolism MP:0005376 10.23 ARID1A ESR2 GPX3 HIF1A HNF1B MET
6 embryo MP:0005380 10.21 ARID1A HIF1A HNF1B MET MTOR PGR
7 muscle MP:0005369 10.14 ARID1A ESR2 HIF1A HNF1B MET MTOR
8 nervous system MP:0003631 10.1 ARID1A ESR2 GPX3 HIF1A HOXA10 MET
9 limbs/digits/tail MP:0005371 10.03 ESR2 HIF1A HOXA10 MET PGR SFRP5
10 neoplasm MP:0002006 10.02 ARID1A CBX7 ESR2 HIF1A MET PGR
11 normal MP:0002873 9.9 ARID1A ESR2 HIF1A MAP4 MET MTOR
12 no phenotypic analysis MP:0003012 9.8 ARID1A ESR2 MET MTOR PGR PIK3CA
13 renal/urinary system MP:0005367 9.61 ANXA4 ESR2 GPX3 HIF1A HNF1B MET
14 skeleton MP:0005390 9.28 ARID1A ESR2 HIF1A HOXA10 MTOR PGR
Sources

Drugs & Therapeutics for Ovarian Clear Cell Adenocarcinoma

About this section

Drugs for Ovarian Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
2 Protein Kinase Inhibitors Phase 2
3 Angiogenesis Inhibitors Phase 2
4
Paclitaxel Approved, Vet_approved 33069-62-4 36314
5 Albumin-Bound Paclitaxel

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma Completed NCT00979992 Phase 2 Sunitinib Malate
2 Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
3 Retrospective Multi-institutional Survey of Clinical Characteristics in Ovarian Clear Cell Adenocarcinoma Cancer Patients Completed NCT02129036

Search NIH Clinical Center for Ovarian Clear Cell Adenocarcinoma

Sources

Genetic Tests for Ovarian Clear Cell Adenocarcinoma

About this section
Sources

Anatomical Context for Ovarian Clear Cell Adenocarcinoma

About this section

MalaCards organs/tissues related to Ovarian Clear Cell Adenocarcinoma:

40
Ovary, Colon, Kidney, Skin, Cervix
Sources

Publications for Ovarian Clear Cell Adenocarcinoma

About this section

Articles related to Ovarian Clear Cell Adenocarcinoma:

(show top 50) (show all 139)
# Title Authors PMID Year
1
Identification of Candidate Genes Associated with Susceptibility to Ovarian Clear Cell Adenocarcinoma Using cis-eQTL Analysis. 61
32316112 2020
2
Synchronous occurrence of primary right ovarian endometrioid adenocarcinoma and primary left ovarian clear cell adenocarcinoma: A case report. 61
29979406 2018
3
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review. 61
29933751 2018
4
Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature. 61
29184869 2017
5
[Ovarian Cancer Rupture Causing Acute Abdomen That Required Emergency Surgery - A Case Report]. 61
28133347 2016
6
Rare and challenging case of stroke as a manifestation of non bacterial thrombotic endocarditis in an underlying ovarian clear cell carcinoma. 61
27833758 2016
7
Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. 61
27660815 2016
8
Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary. 61
27699033 2016
9
Spheroid cancer stem cells display reprogrammed metabolism and obtain energy by actively running the tricarboxylic acid (TCA) cycle. 61
27120812 2016
10
ARID1A gene mutation in ovarian and endometrial cancers (Review). 61
26572704 2016
11
Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary. 61
26397155 2015
12
Optimal cytoreductive surgery for underlying ovarian cancer associated with deep venous thrombosis without placement of inferior vena cava filter: A case report and literature review. 61
26622893 2015
13
The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma. 61
25855053 2015
14
Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. 61
25398420 2015
15
[A Case of Pneumocystis Pneumonia during Chemotherapy for Recurrent Ovarian Cancer]. 61
26197755 2015
16
Napsin A is a specific marker for ovarian clear cell adenocarcinoma. 61
24721826 2015
17
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. 61
25658832 2015
18
Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas. 61
25755836 2015
19
Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. 61
26082939 2014
20
[A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy]. 61
25434451 2014
21
Mass spectrometric analysis of the phosphorylation levels of the SWI/SNF chromatin remodeling/tumor suppressor proteins ARID1A and Brg1 in ovarian clear cell adenocarcinoma cell lines. 61
25083560 2014
22
Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma. 61
25275661 2014
23
A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age. 61
24306200 2014
24
Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. 61
24987918 2014
25
Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. 61
24375438 2014
26
Defect of tropomyosin-related kinase B isotype expression in ovarian clear cell adenocarcinoma. 61
24815386 2014
27
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. 61
24707459 2014
28
Splenic metastasis of ovarian clear cell adenocarcinoma: A case report and review of the literature. 61
24669262 2014
29
Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. 61
24459582 2014
30
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. 61
24504419 2014
31
[A patient with recurrent ovarian clear cell adenocarcinoma and chronic kidney disease exhibited complete response to paclitaxel plus carboplatin]. 61
24196084 2013
32
Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma. 61
23805888 2013
33
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. 61
23430509 2013
34
Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial. 61
23899586 2013
35
Integrative analysis of copy number alteration and gene expression profiling in ovarian clear cell adenocarcinoma. 61
23726144 2013
36
A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies. 61
23502469 2013
37
Stathmin Regulates Hypoxia-Inducible Factor-1α Expression through the Mammalian Target of Rapamycin Pathway in Ovarian Clear Cell Adenocarcinoma. 61
23819061 2013
38
Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. 61
23469222 2013
39
Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells. 61
24244679 2013
40
Clear cell carcinoma of the female genital tract (not everything is as clear as it seems). 61
22885379 2012
41
[Clinical features and drug resistance characteristics of ovarian clear cell adenocarcinoma and analysis of its prognostic factors]. 61
23159083 2012
42
Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma. 61
22871047 2012
43
Aberrant expression of the mammalian target of rapamycin, hypoxia-inducible factor-1α, and glucose transporter 1 in the development of ovarian clear-cell adenocarcinoma. 61
22498943 2012
44
[DNA damage response in ovarian clear cell adenocarcinoma]. 61
22812231 2012
45
Two cases of ovarian clear cell adenocarcinoma producing estradiol. 61
22360511 2012
46
Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture. 61
22317866 2012
47
Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. 61
22101352 2012
48
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. 61
22120431 2012
49
Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. 61
21983935 2012
50
Re-expression of estrogen receptor β inhibits the proliferation and migration of ovarian clear cell adenocarcinoma cells. 61
21874257 2011
Sources

Variations for Ovarian Clear Cell Adenocarcinoma

About this section
Sources

Expression for Ovarian Clear Cell Adenocarcinoma

About this section
Search GEO for disease gene expression data for Ovarian Clear Cell Adenocarcinoma.
Sources

Pathways for Ovarian Clear Cell Adenocarcinoma

About this section

Pathways related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 36
12.46 TP53 PIK3CA MTOR MET HIF1A ESR2
2
Glioma 36
Show member pathways
 12.43 TP53 PIK3CA MTOR MET ESR2
3
ErbB signaling pathway 36 1
Show member pathways
 12.36 TP53 PIK3CA MTOR MET HIF1A
4
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.32 TP53 PIK3CA MTOR MET
5
MicroRNAs in cancer 36
12.26 TP53 STMN1 PIK3CA MTOR MET
6
Apoptosis Pathway 70
Show member pathways
 12.23 TP53 PIK3CA MTOR MET
7
Development IGF-1 receptor signaling 22
Show member pathways
 12.18 TP53 PIK3CA MTOR MET
8
Gastric cancer 36
Show member pathways
 11.89 TP53 SMARCA4 PIK3CA PGR MTOR MET
9
Proteoglycans in cancer 36
11.87 TP53 PIK3CA MTOR MET HIF1A
10
HIF-1 signaling pathway 36
11.78 PIK3CA MTOR HIF1A
11
Thyroid hormone signaling pathway 36
11.71 TP53 PIK3CA MTOR HIF1A
12
Type II diabetes mellitus 36 1
Show member pathways
 11.69 PIK3CA MTOR HNF1B
13
Transcription Ligand-dependent activation of the ESR1/SP pathway 22
Show member pathways
 11.5 SMARCA4 HIF1A ARID1A
14
Pathways Affected in Adenoid Cystic Carcinoma 1
11.45 TP53 PIK3CA ARID1A
15
Central carbon metabolism in cancer 36
11.2 TP53 PIK3CA MTOR MET HIF1A
16
Hypoxic and oxygen homeostasis regulation of HIF-1-alpha 1
10.73 TP53 HIF1A
17
LncRNA-mediated mechanisms of therapeutic resistance 1
10.6 TP53 HIF1A
Sources

GO Terms for Ovarian Clear Cell Adenocarcinoma

About this section

Cellular components related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.28 TP53 SMARCA4 PGR HOXA10 HNF1B HIF1A
2 nBAF complex GO:0071565 9.26 SMARCA4 ARID1A
3 transcription factor complex GO:0005667 9.26 TP53 HOXA10 HNF1B HIF1A
4 npBAF complex GO:0071564 9.16 SMARCA4 ARID1A

Biological processes related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 9.95 TP53 SMARCA4 HNF1B HIF1A ARID1A ANXA4
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.95 TP53 SMARCA4 PGR MET HOXA10 HNF1B
3 negative regulation of transcription by RNA polymerase II GO:0000122 9.91 TP53 SMARCA4 HNF1B ESR2 CBX7 ARID1A
4 positive regulation of transcription, DNA-templated GO:0045893 9.8 TP53 SMARCA4 HNF1B HIF1A ESR2 ARID1A
5 liver development GO:0001889 9.69 PIK3CA MET HNF1B
6 negative regulation of macroautophagy GO:0016242 9.54 PIK3CA MTOR
7 hepatocyte growth factor receptor signaling pathway GO:0048012 9.52 STMN1 MET
8 anoikis GO:0043276 9.49 PIK3CA MTOR
9 positive regulation of transcription of nucleolar large rRNA by RNA polymerase I GO:1901838 9.46 SMARCA4 MTOR
10 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.37 TP53 HIF1A
11 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.33 TP53 SMARCA4 HIF1A
12 negative regulation of guanyl-nucleotide exchange factor activity GO:1905098 9.26 STMN1 MET
13 negative regulation of thrombin-activated receptor signaling pathway GO:0070495 8.96 STMN1 MET
14 regulation of thymocyte apoptotic process GO:0070243 8.62 TP53 HIF1A

Molecular functions related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.8 TP53 PGR HOXA10 HNF1B HIF1A ESR2
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.63 TP53 SMARCA4 PGR HOXA10 HIF1A ESR2
3 protein binding GO:0005515 9.58 WT1-AS TP53 STMN1 SMARCA4 SFRP5 PIK3CA
4 identical protein binding GO:0042802 9.56 TP53 PGR MTOR MET HNF1B GPX3
5 p53 binding GO:0002039 9.43 TP53 SMARCA4 HIF1A
Sources

Sources for Ovarian Clear Cell Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....